ライフサイエンスコーパス: pulmonary vein isolation

1 ed during sinus rhythm after circumferential pulmonary vein isolation.

2 xation time on CMR and freedom from AF after pulmonary vein isolation.

3 ong association with late recurrent AF after pulmonary vein isolation.

4 All patients underwent successful pulmonary vein isolation.

5 (focal impulse and rotor modulation) before pulmonary vein isolation.

6 AD) therapy in patients with previous failed pulmonary vein isolation.

7 mber of patients with nonparoxysmal AF after pulmonary vein isolation.

8 as terminated in 20 patients (38%) after the pulmonary vein isolation.

9 logic study, symptomatic AFL is common after pulmonary vein isolation.

10 All AF patients received circumferential pulmonary vein isolation.

11 standalone procedure or in combination with pulmonary vein isolation.

12 or producing rapid and effective lesions for pulmonary vein isolation.

13 losure was evaluated through 12 months after pulmonary vein isolation.

14 seconds duration 12 months after undergoing pulmonary vein isolation.

15 hic tracing obtained through 12 months after pulmonary vein isolation.

16 of atrial fibrillation (AF) recurrence after pulmonary vein isolation.

17 tion modality, or ablation strategies beyond pulmonary vein isolation.

18 uate the long-term outcome after cryoballoon pulmonary vein isolation.

19 tic paroxysmal atrial fibrillation underwent pulmonary vein isolation.

20 fibrillation after contact force (CF)-guided pulmonary vein isolation.

21 required spot-ablations to complete electric pulmonary vein isolation.

22 is a novel, nonthermal ablation modality for pulmonary vein isolation.

23 nd may require more extensive treatment than pulmonary vein isolation.

24 Patients with paroxysmal AF underwent pulmonary vein isolation.

25 ed during sinus rhythm in 22 patients before pulmonary vein isolation.

26 before video-assisted thoracoscopic surgical pulmonary vein isolation.

27 paroxysmal AF who were scheduled to undergo pulmonary vein isolation.

28 0 patients; 28%) underwent cryoballoon-based pulmonary vein isolation.

29 Randomized control trials comparing PWI to pulmonary vein isolation (3 studies, 444 patients) yield

30 In the group that underwent pulmonary-vein isolation, 88% of patients receiving anti

31 atients undergoing CF-guided circumferential pulmonary vein isolation, 914 radiofrequency application

32 After 1 year post-pulmonary vein isolation, 93 (49%) patients remained AF

33 After successful pulmonary vein isolation, a bonus freeze was applied.

34 Pulmonary vein isolation ablation (n = 79) or previously

35 e contribute to postprocedural evaluation of pulmonary vein isolation ablation.

36 ation for paroxysmal atrial fibrillation and pulmonary vein isolation+/-additional lesions for persis

37 Following pulmonary vein isolation AF drivers (AFDs) were identifi

38 Before pulmonary vein isolation, AF was mapped and then iterati

39 Patients were randomized to either pulmonary vein isolation alone (n = 148) or pulmonary ve

40 on, a limited Cox-Maze procedure (n = 7), or pulmonary vein isolation alone (n = 23).

41 ved in 84 of 148 (56.5%) of those undergoing pulmonary vein isolation alone and in 111 of 154 (72.1%)

42 Pulmonary vein isolation alone cannot explain the discre

43 trial arrhythmias at 12 months compared with pulmonary vein isolation alone for patients with nonparo

44 group, limited Cox-Maze procedure group, and pulmonary vein isolation alone group, respectively.

45 While successful for most patients, pulmonary vein isolation alone is still insufficient for

46 Pulmonary vein isolation alone was much less effective,

47 of VLR in patients who underwent cryoballoon pulmonary vein isolation alone, had an implantable loop

48 procedure, a limited Cox-Maze procedure, or pulmonary vein isolation alone.

49 age ligation and pulmonary vein isolation or pulmonary vein isolation alone.

50 plus pulmonary vein isolation compared with pulmonary vein isolation alone.

51 isolation and 206 were randomized to undergo pulmonary vein isolation alone.

52 -alone group (n = 168) underwent wide antral pulmonary vein isolation alone.

53 n isolation plus posterior wall isolation or pulmonary vein isolation alone.

54 ad undergone cardiac surgery exclusively for pulmonary vein isolation and 17 had no structural heart

55 undergo left atrial appendage ligation plus pulmonary vein isolation and 206 were randomized to unde

56 4.3% with left atrial appendage ligation and pulmonary vein isolation and 59.9% with pulmonary vein i

57 A lower rate of first-pass pulmonary vein isolation and a higher rate of acute pulm

58 All patients underwent pulmonary vein isolation and additional ablation, which

59 During video-assisted thoracoscopic surgical pulmonary vein isolation and CARTO mapping, BrS patients

60 ry, 14 months; Q1-Q3, 7-36 months) underwent pulmonary vein isolation and completed the entire follow

61 d with a circular mapping catheter to assess pulmonary vein isolation and esophageal temperature moni

62 l or persistent AF who underwent cryoballoon pulmonary vein isolation and had an implantable loop rec

63 regulatory trials, the catheter was used for pulmonary vein isolation and left atrial posterior wall

64 During pulmonary vein isolation and left atrial posterior wall

65 cal practice, physicians have ablated beyond pulmonary vein isolation and left atrial posterior wall

66 randomly assigned to (1) standard ablation (pulmonary vein isolation and nonpulmonary vein trigger a

67 rrhythmia recurrences compared with standard pulmonary vein isolation and nonpulmonary vein trigger a

68 ents with nonparoxysmal AF undergoing antral pulmonary vein isolation and nonpulmonary vein trigger a

69 CA consisted of linear antral pulmonary vein isolation and optional additional lines.

70 CA included pulmonary vein isolation and posterior wall isolation.

71 nt AF and 22 with long-lasting AF, underwent pulmonary vein isolation and substrate modification of c

72 We performed pulmonary vein isolation and voltage mapping in 236 pati

73 variable, an ablation strategy that involves pulmonary vein isolation and/or a particular set of abla

74 fibrillation between patients who underwent pulmonary-vein isolation and those who underwent the bia

75 All patients underwent pulmonary vein isolation, and non-pulmonary vein targets

76 and 9 +/- 10 months for the Cox-Maze IV, the pulmonary vein isolation, and the limited Cox-Maze proce

77 In all, 41 patients underwent pulmonary-vein isolation, and 40 underwent atrioventricu

78 ted atrial electrograms (CFAEs) after antral pulmonary vein isolation (APVI) further improves the cli

79 Cryoballoon pulmonary vein isolation as the index procedure for AF a

80 le-lung transplantation surgery both involve pulmonary vein isolation because of suture lines.

81 heters have been shown capable of performing pulmonary vein isolation, but not flexible lesion sets s

82 e-shot PFA catheters have been developed for pulmonary vein isolation, but they do not permit flexibl

83 Current guidelines recommend pulmonary-vein isolation by means of catheter ablation a

84 Left atrial appendage ligation plus pulmonary vein isolation compared with pulmonary vein is

85 At 12 months after pulmonary vein isolation, complete left atrial appendage

86 An anatomic approach to complete pulmonary vein isolation could overcome these limitation

87 Empiric circumferential pulmonary vein isolation (CPVI) has become the therapy o

88 left atrial appendage ligation adjunctive to pulmonary vein isolation did not meet prespecified effic

89 ) and the surgical maze procedure (including pulmonary vein isolation) done during other cardiac surg

90 Pulmonary vein isolation durability was assessed in 28 v

91 After pulmonary vein isolation, electrogram and spatial inform

92 ablation using a stepwise ablation approach (pulmonary vein isolation, electrogram-guided, and linear

93 en; 61 long-lasting persistent AF) underwent pulmonary vein isolation followed by electrogram-guided

94 th PWI group (n = 170) underwent wide antral pulmonary vein isolation followed by posterior wall isol

95 urrence substantially limits the efficacy of pulmonary vein isolation for AF and is associated with p

96 There are concerns that pulmonary vein isolation for atrial fibrillation may hav

97 ial appendage ligation adjunctive to planned pulmonary vein isolation for nonparoxysmal atrial fibril

98 The lesion set comprised pulmonary vein isolation for paroxysmal atrial fibrillat

99 THODS AND Ten consecutive patients underwent pulmonary vein isolation for persistent atrial fibrillat

100 onsecutive patients treated with cryoballoon pulmonary vein isolation for symptomatic AF between 2012

101 Contact force parameters evaluated during pulmonary vein isolation for treating atrial fibrillatio

102 in the Cox-Maze procedure group and 1 in the pulmonary vein isolation group.

103 Although pulmonary vein isolation has become a mainstream therapy

104 Cryoballoon pulmonary vein isolation has become an established treat

105 Pulmonary vein isolation has been the cornerstone for ca

106 ducibility of atrial fibrillation (AF) after pulmonary vein isolation has been used to guide addition

107 Pulmonary vein isolation has increasingly been used to c

108 In humans, variability of CF during pulmonary vein isolation has not been characterized.

109 er, no adjunctive lesion set, in addition to pulmonary vein isolation, has been conclusively demonstr

110 Procedural strategies beyond pulmonary vein isolation have failed to consistently imp

111 uspid isthmus ablation is appropriate during pulmonary vein isolation if AFL has been observed clinic

112 hereas CFAE ablation in addition to standard pulmonary vein isolation improves outcomes in patients w

113 acute), and later than 3 months (late) after pulmonary vein isolation in 25 patients with paroxysmal

114 se, Geneva, Switzerland) was used to perform pulmonary vein isolation in 46 patients with paroxysmal

115 lation strategies in the LAAI group included pulmonary vein isolation in 50 (100%), left atrial isthm

116 Follow-up remapping showed persistent pulmonary vein isolation in all animals (100%) with lesi

117 nt strategy that improves AF outcomes beyond pulmonary vein isolation in all patients.

118 -13 minutes for STA (P<0.001) with confirmed pulmonary vein isolation in all patients.

119 e targeted for ablation, in conjunction with pulmonary vein isolation in most patients (n=19; 79%).

120 ce atrial fibrillation (AF) recurrence after pulmonary vein isolation in patients with paroxysmal AF.

121 The use of second-generation cryoballoon for pulmonary vein isolation in patients with paroxysmal atr

122 ) and cryoballoon catheter (CB) ablation for pulmonary vein isolation in patients with paroxysmal atr

123 g CFAEs have been compared with the standard pulmonary vein isolation in persistent as well as paroxy

124 for prevention of early AF recurrences after pulmonary vein isolation in the absence of antiarrhythmi

125 imary outcomes were ability to achieve acute pulmonary vein isolation intraprocedurally and safety at

126 modification in addition to circumferential pulmonary vein isolation irrespective of AF type.

127 Pulmonary vein isolation is a new, effective curative pr

128 in the first 5 years showed that successful pulmonary vein isolation is achieved in the majority of

129 Pulmonary vein isolation is an effective treatment for A

130 Catheter-based pulmonary vein isolation is an effective treatment for p

131 Pulmonary vein isolation is an established treatment opt

132 Pulmonary vein isolation is better than antiarrhythmic m

133 Pulmonary vein reconnection after pulmonary vein isolation is common and is usually associ

134 its high success and low complication rate, pulmonary vein isolation is expected to be increasingly

135 rial fibrillation (AF) failing to respond to pulmonary vein isolation is important.

136 Pulmonary vein isolation is insufficient to treat all pa

137 The clinical efficacy of pulmonary vein isolation is much lower when AF is persis

138 Pulmonary vein isolation is the cornerstone of ablation

139 Pulmonary vein isolation is the cornerstone of AF ablati

140 Pulmonary vein isolation is the most prevalent approach

141 Pulmonary-vein isolation is an effective treatment for p

142 Pulmonary-vein isolation is increasingly being used to t

143 -4.3 months) of which 3 had AF terminated on pulmonary vein isolation, leaving 27 patients that under

144 went epicardial thoracoscopic radiofrequency pulmonary vein isolation, linear ablation, Marshal ligam

145 se remote from the coronary arteries such as pulmonary vein isolation (n=25 patients) and left atrial

146 Although pulmonary vein isolation of any means/energy source is t

147 n, and (3) The efficacy of PWI compared with pulmonary vein isolation on preventing arrhythmia recurr

148 and pulmonary vein isolation and 59.9% with pulmonary vein isolation only (difference, 4.3% [bayesia

149 more frequent (68% versus 59%; P<0.001), and pulmonary vein isolation-only was more frequent (93% ver

150 Pulmonary vein isolation-only was used in 90% of the pat

151 l fibrillation before electric cardioversion/pulmonary vein isolation or after cardioembolic cerebrov

152 tor for stroke at 126 sites to ablation with pulmonary vein isolation or drug therapy including rate

153 o undergo left atrial appendage ligation and pulmonary vein isolation or pulmonary vein isolation alo

154 ion group underwent further randomization to pulmonary-vein isolation or a biatrial maze procedure.

155 ss II or III heart failure to undergo either pulmonary-vein isolation or atrioventricular-node ablati

156 voltage zones, recovery of posterior wall or pulmonary vein isolation, or other sustaining mechanisms

157 mary effectiveness end point (PEE) was acute pulmonary vein isolation plus freedom from any atrial ar

158 Ablation was performed by circumferential pulmonary vein isolation plus linear ablation of extrapu

159 randomized patients with symptomatic PsAF to pulmonary vein isolation plus posterior wall isolation o

160 nd in 111 of 154 (72.1%) of those undergoing pulmonary vein isolation plus renal denervation (hazard

161 pulmonary vein isolation alone (n = 148) or pulmonary vein isolation plus renal denervation (n = 154

162 reablation after a previously failed initial pulmonary vein isolation procedure were eligible for thi

163 Median (Q1, Q3) pulmonary vein isolation procedure, fluoroscopy, and tra

164 rwent cardiac MRI in sinus rhythm prior to a pulmonary vein isolation procedure.

165 s after an apparently successful cryoballoon pulmonary vein isolation procedure.

166 ODS AND We analyzed 42 CF-guided ipsilateral pulmonary vein isolation procedures.

167 In the group that underwent pulmonary-vein isolation, pulmonary-vein stenosis develo

168 he ablation group were further randomized to pulmonary vein isolation (PVI) (n = 62) or the biatrial

169 ike for paroxysmal atrial fibrillation (AF), pulmonary vein isolation (PVI) alone is considered insuf

170 Pulmonary vein isolation (PVI) alone is less effective i

171 atrial arrhythmia at 12 months compared with pulmonary vein isolation (PVI) alone.

172 to compare arrhythmia-free survival between pulmonary vein isolation (PVI) and a stepwise approach (

173 cryoballoon is effective in achieving acute pulmonary vein isolation (PVI) and favorable clinical ou

174 o propensity-score matched cohorts, one with pulmonary vein isolation (PVI) and linear ablation inclu

175 ave been developed to achieve more effective pulmonary vein isolation (PVI) and minimize arrhythmia r

176 ecurrences of atrial fibrillation (AF) after pulmonary vein isolation (PVI) are mainly due to pulmona

177 ibrillation (PerAF), in which lesions beyond pulmonary vein isolation (PVI) are often placed.

178 for atrial fibrillation (AF) has established pulmonary vein isolation (PVI) as a key target for AF ab

179 es recommend a 3-month blanking period after pulmonary vein isolation (PVI) as early recurrence of at

180 Pulmonary vein isolation (PVI) as interventional treatme

181 Atrial fibrillation (AF) may recur after pulmonary vein isolation (PVI) as the result of either r

182 nd-generation cryoballoon delivers effective pulmonary vein isolation (PVI) associated with superior

183 can be challenging, often involving not only pulmonary vein isolation (PVI) but also additional linea

184 gate whether the combination of conventional pulmonary vein isolation (PVI) by circumferential antral

185 Pulmonary vein isolation (PVI) for atrial fibrillation i

186 Pulmonary vein isolation (PVI) for persistent atrial fib

187 ess and complications in patients undergoing pulmonary vein isolation (PVI) for treatment of atrial f

188 For the past decade, electric pulmonary vein isolation (PVI) has become a procedure im

189 Although pulmonary vein isolation (PVI) has become the cornerston

190 imed to determine the safety and efficacy of pulmonary vein isolation (PVI) in atrial fibrillation (A

191 s the impact of CFAE ablation in addition to pulmonary vein isolation (PVI) in patients undergoing ab

192 nts the gold standard single-shot device for pulmonary vein isolation (PVI) in patients with atrial f

193 Pulmonary vein isolation (PVI) is a recommended treatmen

194 Pulmonary vein isolation (PVI) is an effective treatment

195 ation (PersAF), catheter ablation aiming for pulmonary vein isolation (PVI) is associated with modera

196 Arrhythmia recurrence after pulmonary vein isolation (PVI) is common.

197 The single-procedure efficacy of pulmonary vein isolation (PVI) is less than optimal in p

198 Pulmonary vein isolation (PVI) is still associated with

199 It is not known whether complete pulmonary vein isolation (PVI) is superior to incomplete

200 tions include not only the durability of the pulmonary vein isolation (PVI) lines, but also the patho

201 We hypothesized that pulmonary vein isolation (PVI) plus ablation of selectiv

202 with persistent AF were randomly assigned to pulmonary vein isolation (PVI) plus MRI-guided atrial fi

203 Pulmonary vein isolation (PVI) represents the cornerston

204 Despite the fact that pulmonary vein isolation (PVI) should be performed proph

205 eld ablation (PFA) has gained prominence for pulmonary vein isolation (PVI) to treat atrial fibrillat

206 efficacy and safety of combining cryoballoon pulmonary vein isolation (PVI) with SVC ablation compare

207 Background Although proposed to facilitate pulmonary vein isolation (PVI), high-power ablation may

208 esonance (CMR)-detected atrial fibrosis plus pulmonary vein isolation (PVI).

209 confidence level >7 were ablated followed by pulmonary vein isolation (PVI).

210 ith obstructive sleep apnea (OSA) undergoing pulmonary vein isolation (PVI).

211 AF/AT recurrence is common after pulmonary vein isolation (PVI).

212 nitial ablation strategy was circumferential pulmonary vein isolation (PVI).

213 resistant hypertension who were referred for pulmonary vein isolation (PVI).

214 ons have proven to be safe and efficient for pulmonary vein isolation (PVI).

215 transesophageal echocardiogram (TEE) before pulmonary vein isolation (PVI); and 2) the relationship

216 has shown impressive efficacy and safety for pulmonary vein isolation (PVI); however, initial efficac

217 In CF-guided pulmonary vein isolation, PVR is explained by lack of bo

218 in patients undergoing robotically assisted pulmonary vein isolation (RA-PVI) as compared with manua

219 On a pulmonary vein basis, pulmonary vein isolation rate was 100% including a singl

220 CF during pulmonary vein isolation remains highly variable despite

221 in isolation, use of a nonstudy catheter for pulmonary vein isolation, repeat procedure (except for o

222 Pulmonary vein isolation resulted in a statistically sig

223 Antral pulmonary vein isolation resulted in termination of AF i

224 ablation at these sites, in conjunction with pulmonary vein isolation, resulted in AF termination or

225 ion to investigate the hypothesis that acute pulmonary vein isolation results from a combination of i

226 e of second-generation 28-mm cryoballoon for pulmonary vein isolation results in an 80% 1-year succes

227 In patients undergoing pulmonary vein isolation, RFA juxtaposed to the esophagu

228 nt this stalemate, safer, and more effective pulmonary vein isolation seems increasingly realistic.

229 The contact force during pulmonary vein isolation should be a target of 10-20 g o

230 icular contractions at the large majority of pulmonary vein isolation sites.

231 h a conventional ablation approach was used (pulmonary vein isolation/stepwise approach).

232 In addition to pulmonary vein isolation, substrate modification and tri

233 y Holter monitoring at 6 and 12 months after pulmonary vein isolation, symptomatic event monitoring,

234 ciation between LAPEF and recurrent AF after pulmonary vein isolation that persisted after multivaria

235 uency ablation is the dominant technique and pulmonary vein isolation the principal lesion set.

236 The pulmonary vein isolation therapy duration time (transpir

237 onitoring in the ADVICE (Adenosine Following Pulmonary Vein Isolation to Target Dormant Conduction El

238 on techniques may facilitate safe and simple pulmonary vein isolation to treat paroxysmal atrial fibr

239 Complete pulmonary vein isolation to v an end point of eliminatio

240 atrial flutter) episodes, failure to achieve pulmonary vein isolation, use of a nonstudy catheter for

241 line pulsed field ablation catheter achieves pulmonary vein isolation using 8 stacked, pose-specific

242 aroxysmal AF, planned for first CLOSE-guided pulmonary vein isolation using a contact force radiofreq

243 se evaluated the feasibility and efficacy of pulmonary vein isolation using a novel PFA system delive

244 ed tomography (CT) before and 3 months after pulmonary vein isolation using duty-cycled phased radio

245 balloon (LB) with wide-area circumferential pulmonary vein isolation using irrigated radiofrequency

246 imilar efficacy as wide-area circumferential pulmonary vein isolation using irrigated RF in patients

247 Pulmonary vein isolation using PFA for paroxysmal atrial

248 We report on bronchial effects after pulmonary vein isolation using PFA for paroxysmal atrial

249 tiarrhythmic drug(s), who were scheduled for pulmonary vein isolation using second-generation cryobal

250 Pulmonary vein isolation using standard radiofrequency a

251 llows for simple and safe simple single shot pulmonary vein isolation using standard sedation protoco

252 udy confirms the safety and effectiveness of pulmonary vein isolation using the novel 3-dimensional m

253 ulceration and fistula are complications of pulmonary vein isolation using thermal energy sources.

254 risk of pulmonary vein narrowing (PVN) after pulmonary vein isolation, using a novel multi-electrode

255 educing AF recurrence, SOE was high favoring pulmonary vein isolation versus antiarrhythmic medicatio

256 roke to a strategy of catheter ablation with pulmonary vein isolation versus drug therapy with rate/r

257 Multielectrode pulmonary vein isolation versus single tip wide area cat

258 Pulmonary vein isolation was achieved in 99.2% of patien

259 Successful pulmonary vein isolation was achieved in all participant

260 In this first-in-human clinical study, 100% pulmonary vein isolation was achieved using only PFA wit

261 Pulmonary vein isolation was complete in 338 of the 358

262 Pulmonary vein isolation was confirmed by intraoperative

263 Pulmonary vein isolation was performed in 133 consecutiv

264 Pulmonary vein isolation was performed in 227 patients (

265 Pulmonary vein isolation was performed in 93% of patient

266 Pulmonary vein isolation was performed in 94.6% of de no

267 Pulmonary vein isolation was performed in 99.8% of femal

268 Pulmonary vein isolation was performed in all patients,

269 udy included 140 patients (43 women) in whom pulmonary vein isolation was performed using a second-ge

270 l (35 W), whereas in the experimental group, pulmonary vein isolation was performed using high power

271 Pulmonary vein isolation was performed with a cryoballoo

272 Pulmonary vein isolation was performed with a variable-l

273 Pulmonary vein isolation was the primary ablation approa

274 Pulmonary vein isolation was undertaken in each patient

275 Pulmonary-vein isolation was superior to atrioventricula

276 0 males, 57.8+/-8.7 years old) who underwent pulmonary vein isolation were enrolled.

277 th paroxysmal atrial fibrillation undergoing pulmonary vein isolation were followed for 12 months wit

278 etic resonance pulmonary vein mapping before pulmonary vein isolation were included.

279 nts with atrial fibrillation despite durable pulmonary vein isolation were randomly assigned at 7 cen

280 s circular lesions, deep enough for electric pulmonary vein isolation, were created with a single cir

281 in the left atrium and coronary sinus after pulmonary vein isolation, were enrolled.

282 brillation (AF) recurrences than wide antral pulmonary vein isolation (wide antral isolation [WAI]) b

283 iarrhythmic drugs (class I or III agents) or pulmonary vein isolation with a cryoballoon.

284 Ablation included pulmonary vein isolation with confirmed entrance block a

285 rticipants were randomly assigned to receive pulmonary vein isolation with cryoablation (n = 64) or a

286 receive radiofrequency catheter ablation for pulmonary vein isolation with either a standard single W

287 Pulmonary vein isolation with PWI vs PVI alone.

288 Pulmonary vein isolation, with additional ablation proce

289 catheter ablation group (n = 1108) underwent pulmonary vein isolation, with additional ablative proce

290 is to identify those who will not respond to pulmonary vein isolation, with novel approaches to pheno

291 y end point favored the group that underwent pulmonary-vein isolation, with an improved questionnaire

292 had similar rates of single-procedure acute pulmonary vein isolation without serious adverse events